Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT05464030Phase 1Active, not recruiting
- Sponsor
- EMD Serono
- Start
- Aug 2022
- Primary completion
- Oct 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of precemtabart tocentecan in colorectal cancer (CRC) (5 arms), sponsored by EMD Serono. Primary endpoints: Dose Limiting Toxicities at 8 months, Adverse Events at 8 months and 3 more. Started Aug 2022; status: active, not recruiting.
02
Drugs
precemtabart tocentecan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05464030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05464030.